Table 2.
Clinical stage before and after CRT plus apatinib treatment
| Clinical stage | Before CRT plus apatinib treatment (n=30) | After CRT plus apatinib treatment (n=30) | P value |
|---|---|---|---|
| Clinical T stage, No. (%) | <0.001 | ||
| cT2 | 0 (0.0) | 8 (26.7) | |
| cT3 | 2 (6.7) | 7 (23.3) | |
| cT4 | 28 (93.3) | 15 (50.0) | |
| Clinical N stage, No. (%) | <0.001 | ||
| N0 | 0 (0.0) | 22 (73.3) | |
| N1 | 13 (43.3) | 8 (26.7) | |
| N2 | 12 (40.0) | 0 (0.0) | |
| N3 | 5 (16.7) | 0 (0.0) | |
| Clinical M stage, No. (%) | 0.317 | ||
| M0 | 30 (100.0) | 29 (96.7) | |
| M1 | 0 (0.0) | 1 (3.3) | |
| Clinical TNM stage, No. (%) | <0.001 | ||
| Stage I | 0 (0.0) | 8 (26.7) | |
| Stage II | 0 (0.0) | 12 (40.0) | |
| Stage III | 30 (100.0) | 9 (30.0) | |
| Stage IV | 0 (0.0) | 1 (3.3) | |
| Successful down-staging | - | 20 (66.7) | - |
CRT, chemoradiotherapy.